Prodromos Sidiropoulos
About
In The Last Decade
Prodromos Sidiropoulos
158 papers receiving 5.3k citations
Hit Papers
Peers
Comparison fields: 5 of 134
- Rheumatology 2.9k
- Immunology 2.4k
- Molecular Biology 1.1k
- Hematology 594
- Epidemiology 550
Countries citing papers authored by Prodromos Sidiropoulos
This map shows the geographic impact of Prodromos Sidiropoulos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Prodromos Sidiropoulos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Prodromos Sidiropoulos more than expected).
Fields of papers citing papers by Prodromos Sidiropoulos
This network shows the impact of papers produced by Prodromos Sidiropoulos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Prodromos Sidiropoulos. The network helps show where Prodromos Sidiropoulos may publish in the future.
Co-authorship network of co-authors of Prodromos Sidiropoulos
This figure shows the co-authorship network connecting the top 25 collaborators of Prodromos Sidiropoulos. A scholar is included among the top collaborators of Prodromos Sidiropoulos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Prodromos Sidiropoulos. Prodromos Sidiropoulos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | 1 | |
| 3 | 3 | |
| 4 | 11 | |
| 5 | 5 | |
| 6 | 6 | |
| 7 | 4 | |
| 8 | 1 | |
| 9 | 18 | |
| 10 | 71 | |
| 11 | 79 | |
| 12 | 85 | |
| 13 | 2 | |
| 14 | Liver safety of non-tumour necrosis factor inhibitors in rheumatic patients with past hepatitis B virus infection: an observational, controlled, long-term study. | 29 |
| 15 | Is it primary neuropsychiatric systemic lupus erythematosus? Performance of existing attribution models using physician judgment as the gold standard. | 26 |
| 16 | Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database. | 22 |
| 17 | 22 | |
| 18 | Geriatric rheumatoid arthritis patients on delayed anti-TF-alpha agents have higher disease activity and experience more often serious adverse events compared to younger adults | 1 |
| 19 | High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNFalpha treatment: correlation with disease activity. | 59 |
| 20 | Long-term follow-up of RA patients of the Hellenic Biologics Registry: comparison of first versus second anti-TNF-alpha therapy | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.